Core Insights - Madrigal Pharmaceuticals, Inc. has established itself as a leader in the MASH market, achieving nearly $1 billion in Rezdiffra sales in its first full year of launch, with expectations for continued growth in 2026 driven by increased market penetration and disease awareness [2][5]. Financial Performance - Fourth-quarter 2025 net sales for Rezdiffra reached $321.1 million, while full-year sales totaled $958.4 million, a significant increase from $103.3 million and $180.1 million in the prior year periods [5][8]. - Operating expenses for the fourth quarter and full year were $380.7 million and $1,258.5 million, respectively, compared to $170.3 million and $678.0 million in the previous year [8][19]. - The company reported a net loss of $58.6 million for the fourth quarter and $288.3 million for the full year, with basic and diluted net loss per share of $2.57 and $12.85, respectively [19]. Pipeline and Product Development - Madrigal has built an industry-leading MASH pipeline with over 10 programs at various stages of development, including licensed global rights to six pre-clinical siRNA programs aimed at genetically targeted treatments [5][6]. - The company has expanded its pipeline with an exclusive global license for ervogastat, a phase 2 oral DGAT-2 inhibitor, which has shown promising results in reducing liver fat in patients [6][7]. - MGL-2086, an oral GLP-1 receptor agonist, is expected to enter clinical trials in the second quarter of 2026, further enhancing the company's combination treatment strategy [9]. Market Position and Strategy - Madrigal's Rezdiffra is the first and only approved therapy for MASH in the European Union, following its launch in Germany after receiving conditional marketing authorization [9][10]. - The company has secured a patent for Rezdiffra that extends protection until 2045, reinforcing its competitive position in the market [6][7]. - Madrigal aims to address the needs of approximately 315,000 patients with moderate to advanced fibrosis in the U.S., highlighting the significant market opportunity as disease awareness and prevalence increase [12][13].